|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||225.52 - 228.41|
|52 Week Range||177.05 - 264.97|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||18.30|
|Forward Dividend & Yield||6.40 (2.82%)|
|Ex-Dividend Date||Nov 13, 2020|
|1y Target Est||N/A|
Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.
Top Stock Reports for Facebook, Netflix & AbbVie
This coming weekend, doctors who treat blood disorders will convene virtually to discuss new treatments that are extending the lives of patients.